Docetaxel, Vinorelbine and Trastuzumab in the Treatment of Patients With Metastatic Her-2 Positive Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Docetaxel|DRUG: Vinorelbine|DRUG: Trastuzumab
Sponsor: SCRI Development Innovations, LLC
Collaborators: Aventis Pharmaceuticals|GlaxoSmithKline